3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

A compound according to formula (I)

• wherein:
• R1 is hydrogen, methyl or ethyl;
• R2a is hydrogen, methyl or C1-3 haloalkyl;
• R2b is OH, halo, C1-6 alkoxy, C1-3 haloalkyl, NH2, NH(CH3) or N(CH3)2;
• R3 and R4 are each independently hydrogen, methyl or ethyl or R3 and R4 are joined together forming cyclopropyl, cyclobutyl or oxetanyl;
• R5 and R6 are each independently hydrogen, deuterium, halo, —C(O)OCH3, C1-3 alkyl or C1-3 haloalkyl;
• R7 is
• wherein:
• ring A is a 6 membered heteroaryl ring having one to three nitrogen atoms;
• ring B is a 5 membered heteroaryl ring having one to four heteroatoms each independently selected from the group consisting of N, O and S;
• X is N or CH;
• each R8 is independently hydrogen, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy or C1-3 haloalkoxy;
• n is 1 or 2;
• R9 is hydrogen, halo, C1-3 haloalkyl, optionally substituted C1-6 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted aryl, optionally substituted 5 or 6 membered heterocyclic, optionally substituted heteroaryl, —OR9a, —SO2R9a, —C(O)NHR9a, CH2R9b or CHCH3R9b, provided that when X is N, R9 is hydrogen, C1-3 haloalkyl, optionally substituted C1-6 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —SO2R9a or —C(O)NHR9a, wherein:
• said C1-6 alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of:
• OH, phenyl and phenoxy, and
• Said C3-6 cycloalkyl, 5 or 6 membered heterocyclic, aryl and heteroaryl are each optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, —NRR, C1-6 alkyl, C1-6 haloalkyl, C1-3 alkoxy, and C1-3 haloalkoxy;
• R9a is optionally substituted C1-6 alkyl, C1-6 haloalkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted heterocyclic,
• wherein:
• said C1-6 alkyl is optionally substituted with one C3-6 cycloalkyl,
• Said C3-6 cycloalkyl and heterocyclic are each optionally substituted with one to three substituents each independently selected from the group consisting of:
• hydroxyl, CH2OH, —NRR, cyano, C1-3 alkyl, C1-3 haloalkyl, and C1-3 alkoxy, and
• Said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, —NRR, C1-6 alkyl, C1-6 haloalkyl, C1-3 alkoxy, and C1-3 haloalkoxy;
• R9b is optionally substituted C3-6 cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclic,
• said C3-6 cycloalkyl and heterocyclic are each optionally substituted with one to four substituents each independently selected from the group consisting of:
• hydroxyl, CH2OH, —NRR, —NRC(O)CH3, 4 to 6 membered heterocyclic, cyano, halo, C1-3 alkyl, C1-3 haloalkyl, and C1-3 alkoxy, and
• Said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, C1-6 alkyl, Cl—6 haloalkyl, C1-3 alkoxy, and C1-3 haloalkoxy;
• and
• each R is independently selected from the group consisting of H, C1-3 alkyl and C3-6 cycloalkyl;
• or a pharmaceutically acceptable salt thereof.